Celularity IncCELU

Celularity Inc filed a 10-K for the year ended 31 December 2025 that lists $26.6 million of revenue and a net loss of $91.7 million, leaving shareholders’ equity at negative $38.1 million and cash on hand at $6.2 million. Net cash used in operating activities was $13.3 million, so every headline about sevenfold product sales growth has to be read against a backdrop of accelerating cash burn. (source: SEC EDGAR 10-K, period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1752828/000149315226031216/form10-k.htm)

Celularity is a cell-based medicine outfit built around placental biomaterials, contract development and manufacturing, and a biobanking service, with a pipeline anchored on placental-derived allogeneic cell therapies such as cenplacel-L. The company’s own materials say it has “abundant capacity” and “existing inventory” ready for anticipated demand, yet the 10-K shows only $571,000 of inventory on the balance sheet and $15.0 million in R&D spend, figures that paint a pilot-scale operation rather than a scaled product business. (source: SEC EDGAR 10-K, period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1752828/000149315226031216/form10-k.htm)

The 10-K also reports liabilities of $145.4 million against assets of $107.3 million, which is a structural deficit that turns the “equity attributable to parent” into a negative $38.1 million entry. Diluted EPS for the year was negative $3.59 on 25.6 million diluted shares, and net cash used in operations was negative $13.3 million, so dilution and cash burn are already the dominant story before any product approvals or sales acceleration. The company’s latest 25-NSE filing shows inventory fell by another $10.2 million in the period, a line that sits awkwardly beside the CEO letter’s claim of “existing inventory position.” (source: SEC EDGAR 10-K, period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1752828/000149315226031216/form10-k.htm; SEC EDGAR 25-NSE (2026-07-22), https://www.sec.gov/Archives/edgar/data/1752828/000135445726000719/xslF25X02/primary_doc.xml)

The company’s press room touts FDA Tissue Reference Group recommendation letters for Natalin and Acelagraft wound-care products, and a 2024 news release claimed over sevenfold growth in net product sales versus the prior year. Those releases sit in the same folder as the 10-K’s $6.2 million cash position and negative equity, so the market is left to reconcile marketing claims with filing reality. There is no SEC filing or independent audit that converts the “sevenfold growth” press release into audited 2025 revenue numbers, leaving investors to judge how much of the 2024 surge carried into 2025. (source: Celularity press releases, https://celularity.com/press-releases/)

The latest CEO letter to shareholders asserts Celularity has “abundant capacity” and “existing inventory position” to meet anticipated demand, yet the 10-K shows $571,000 of inventory and a negative $38.1 million equity line. The same letter announces a new commercial lead tasked with expanding physician access to cenplacel-L, an initiative that may take quarters to show up in the cash-flow statement. Until the company files audited financials that show sustained revenue above $26 million, positive operating cash flow, and a path to positive equity, the polished platform story remains a bridge too far from the balance sheet facts. (source: Celularity CEO letter to shareholders 2, https://celularity.com/celularity-releases-ceo-letter-to-shareholders-2/)

The pipeline page insists Celularity is “only in the early stages of unlocking the full potential” of its IMPACT platform, a placental-derived allogeneic cell therapy platform. The filing evidence, however, shows $15.0 million of R&D spend, $6.2 million of cash, and negative $38.1 million equity, which suggests early-stage economics rather than commercial-scale economics. Management may believe in the science, but the balance sheet is where the belief meets the banker’s calculator. (source: Celularity pipeline page, https://celularity.com/pipeline/)